Drug recall · August 24, 2016
Glipizide 2.5 mg Extended-release tablets recall
Why: Failed Dissolution Specifications: Glipizide 2.5 mg ER Tablets exceeded dissolution specification rates for the 10 hour testing point.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Glipizide 2.5 mg Extended-release tablets, 30-count bottle, Rx Only, Manufactured By: Patheon Pharmaceuticals Inc Cincinnati, OH 45237, NDC 00591-0900-30
- Lots / codes
Lot # 3132593, 3132594, 3134420, 3134421,3134422, Exp. 02/17
- Quantity
- 167,152 bottles
- Company
- Actavis Inc, Parsippany, NJ
- Distribution
- Nationwide
- Initiated
- June 30, 2016 · Voluntary: Firm initiated
- Classified
- August 15, 2016
- Reported
- August 24, 2016
- Ended
- July 3, 2017
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Glipizide
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.